Arcus Biosciences (RCUS) Tops Q4 EPS by 20c
Tweet
Share
E-mail
Get Alerts RCUS Hot Sheet
Join SI Premium – FREE
Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($1.03), $0.20 better than the analyst estimate of ($1.23). Revenue for the quarter came in at $36 million versus the consensus estimate of $29.33 million.
For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: Walmart will be lowering prices
- Bernstein SocGen Group Reiterates Outperform Rating on Tencent Holdings (700:HK) (TCEHY)
- Goldman Sachs Starts SpaceX (SPCX) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
